ZIVO BIOSCIENCE INC - ZIVO STOCK NEWS

Zivo Bioscience, Inc. (NASDAQ: ZIVO) announced a $1 million unsecured loan from its CEO, John Payne, to support working capital and a validation study for its coccidiosis treatment for broiler chickens. The loan has a 10% interest rate and includes warrants for 390,000 shares at $2.91 each. The company aims to validate its immune-modulating product, with results expected by mid-2023. Payne expressed confidence in Zivo's team and strategies, while CFO Keith Marchiando emphasized the significance of this support for funding beyond the current study. Zivo also continues to scale up production for the human food industry, showcasing its commitment to both animal and human health avenues.

Zivo Bioscience (NASDAQ: ZIVO) announced disappointing results from a recent study on a novel immune-modulating product for coccidiosis treatment in broiler chickens, conducted by a third party. The trial faced a significantly higher than usual mortality rate due to an intense disease challenge, yielding results not reflective of commercial production conditions. Despite this setback, ZIVO remains confident in its product's potential and plans to conduct a new study, expected to conclude by mid-year. The company continues to prioritize coccidiosis treatment while exploring additional health benefits from its proprietary algal cultures.

Zivo Bioscience has announced the formation of a wholly-owned subsidiary, ZIVOLife, which will hold an exclusive worldwide limited license to utilize the company's intellectual property for producing and supplying whole biomass algal products. This strategic move aims to enhance its corporate structure, capitalize on agtech market opportunities, and expedite revenue generation. Upon finalizing a license agreement, Zivo is set to receive royalty payments from ZIVOLife. A conference call is planned for early November to discuss these developments.

Zivo Bioscience, Inc. (NASDAQ: ZIVO) continues to focus on maximizing its product portfolio value derived from proprietary algal cultures. In a letter to shareholders, CEO John Payne highlights efforts in restructuring the company to drive revenue through two key initiatives: a biotech strategy targeting coccidiosis treatment in poultry and an agtech strategy aimed at commercial-scale production of nutritional products. The company aims to establish partnerships and scale manufacturing to enhance revenue generation, while ongoing studies may lead to product validation and regulatory approvals.

ZIVO Bioscience (NASDAQ: ZIVO) has received confirmation from the U.S. Department of Agriculture's Center for Veterinary Biologics of its jurisdiction over ZIVO's novel immune-modulating biologic for coccidiosis in broiler chickens. This parasitic disease affects poultry welfare and costs the industry over $1.5 billion annually. With regulatory clarity established, ZIVO is poised to expedite its product approval path and enhance its discussions on product development and regulatory strategy to maximize market potential.

ZIVO Bioscience, Inc. (NASDAQ: ZIVO) has been added to the Russell Microcap® Index as of June 27, 2022, following the annual reconstitution. This membership will last for one year and enhances ZIVO's visibility among institutional investors, aiming to boost growth expectations. The Russell indexes, benchmarked by $12 trillion in assets, reflect market capitalization and style. CEO John Payne expressed optimism about increased investor interest and broadened stock exposure through this inclusion, which aligns with the company's ongoing strategy in biotech and agtech sectors.

ZIVO Bioscience, Inc. (NASDAQ: ZIVO) announced that it has regained compliance with Nasdaq Listing Rule 5250(c)(1), following a prior notice of noncompliance for not filing its Annual Report on Form 10-K for the year ended December 31, 2021. After filing the report on April 22, 2022, ZIVO received confirmation from Nasdaq on April 25, 2022, that it met the listing requirements again. The company focuses on R&D for therapeutic and nutritional products derived from algal cultures.